Return to homepagePandemic Pact

reCOVer - Autoantibodies against G protein-coupled receptors as a harmful agent for the microcirculation as a cause of symptom persistence in "Long-COVID" - Subproject A

  • Funded by Federal Ministry of Research, Technology and Space (BMFTR)
  • Total publications:4 publications

Grant number: 01EP2108A

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2024

  • Known Financial Commitments (USD)

    $991,846.28

  • Funder

    Federal Ministry of Research, Technology and Space (BMFTR)

  • Research Location

    Germany

  • Lead Research Institution

    Friedrich-Alexander-Universität Erlangen-Nürnberg

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

4 Publications linked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

Imbalanced Trace Elements as Risk Factors in the Pathogenesis of Glaucoma.

Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT).

Functional Autoantibodies Targeting G-Protein-Coupled Receptors and Their Clinical Phenotype in Patients with Long-COVID.

Long COVID: Association of Functional Autoantibodies against G-Protein-Coupled Receptors with an Impaired Retinal Microcirculation.